Do you ever perform adaptive replanning for interfraction tumor volume changes appreciated during a fractionated SRS ( 5 fx) treatment for CNS metastases?
In particular, if the tumor volume has decreased would you consider adapting the plan to reduce risk for toxicity considering healthy brain tissue / pushing margin would be closer to the center of the treatment volume with higher doses.